Artelo Biosciences Inc
Company Profile
Business description
Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors & neurotransmitters that form a biochemical communication network in the body. It is focused on discovering, licensing, developing, & commercializing treatments that control endocannabinoid systems. The company pursues technologies & programs that offer proprietary approaches to cannabinoid-based therapies, & those derived from the cannabis plant & synthetic cannabinoids, as well as new chemical entities & compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare & orphan disease.
Contact
505 Lomas Santa Fe
Suite 160
Solana BeachCA92075
USAT: +1 858 925-7049
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
6
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,808.80 | 17.90 | -0.20% |
| CAC 40 | 7,902.25 | 23.79 | 0.30% |
| DAX 40 | 24,456.81 | 92.75 | -0.38% |
| Dow JONES (US) | 44,650.64 | 192.34 | 0.43% |
| FTSE 100 | 8,975.66 | 108.64 | 1.23% |
| HKSE | 24,400.68 | 372.31 | 1.55% |
| NASDAQ | 20,630.66 | 19.33 | 0.09% |
| Nikkei 225 | 39,602.15 | 44.21 | -0.11% |
| NZX 50 Index | 12,690.00 | 70.20 | -0.55% |
| S&P 500 | 6,280.46 | 17.20 | 0.27% |
| S&P/ASX 200 | 8,568.80 | 20.40 | -0.24% |
| SSE Composite Index | 3,534.69 | 25.01 | 0.71% |